These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37870961)

  • 41. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
    Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
    Oliveira C; Velho S; Moutinho C; Ferreira A; Preto A; Domingo E; Capelinha AF; Duval A; Hamelin R; Machado JC; Schwartz S; Carneiro F; Seruca R
    Oncogene; 2007 Jan; 26(1):158-63. PubMed ID: 16953233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism.
    Colangelo T; Carbone A; Mazzarelli F; Cuttano R; Dama E; Nittoli T; Albanesi J; Barisciano G; Forte N; Palumbo O; Graziano P; di Masi A; Colantuoni V; Sabatino L; Bianchi F; Mazzoccoli G
    Cell Death Differ; 2022 Aug; 29(8):1552-1568. PubMed ID: 35034102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
    Yun J; Mullarky E; Lu C; Bosch KN; Kavalier A; Rivera K; Roper J; Chio II; Giannopoulou EG; Rago C; Muley A; Asara JM; Paik J; Elemento O; Chen Z; Pappin DJ; Dow LE; Papadopoulos N; Gross SS; Cantley LC
    Science; 2015 Dec; 350(6266):1391-6. PubMed ID: 26541605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
    Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
    Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Martianov AS; Mitiushkina NV; Ershova AN; Martynenko DE; Bubnov MG; Amankwah P; Yanus GA; Aleksakhina SN; Tiurin VI; Venina AR; Anuskina AA; Gorgul YA; Shestakova AD; Maidin MA; Belyaev AM; Baboshkina LS; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA Expression in
    Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
    Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer.
    Krebs AM; Mitschke J; Lasierra Losada M; Schmalhofer O; Boerries M; Busch H; Boettcher M; Mougiakakos D; Reichardt W; Bronsert P; Brunton VG; Pilarsky C; Winkler TH; Brabletz S; Stemmler MP; Brabletz T
    Nat Cell Biol; 2017 May; 19(5):518-529. PubMed ID: 28414315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition.
    Liu Z; Sun B; Qi L; Li H; Gao J; Leng X
    Cancer Sci; 2012 Apr; 103(4):813-20. PubMed ID: 22212097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers.
    Mahmoud A; Elkhalifa D; Alali F; Al Moustafa AE; Khalil A
    Curr Pharm Des; 2020; 26(14):1622-1633. PubMed ID: 32026770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
    Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
    Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
    He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
    Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.